Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

659
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
659
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

156
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
156
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

543
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
543

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM.

American journal of preventive cardiology·2026
Same author

Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT.

European journal of preventive cardiology·2025
Same author

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.

European heart journal·2024
Same author

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.

European heart journal open·2023
Same author

Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data.

European heart journal. Digital health·2023
Same author

Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy.

Circulation·2021

Related Experiment Video

Updated: Jun 29, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

Michael Szarek1, Deepak L Bhatt2, Michael Miller3

  • 1Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; CPC Clinical Research, Aurora, Colorado, USA; State University of New York, Downstate Health Sciences University, Brooklyn, New York, USA.

Journal of the American College of Cardiology
|March 26, 2024
PubMed
Summary
This summary is machine-generated.

Icosapent ethyl (IPE) effectively lowers cardiovascular event risk in individuals with elevated lipoprotein(a) [Lp(a)], regardless of Lp(a) levels. This finding is crucial for managing residual cardiovascular risk in patients on statin therapy.

Keywords:
Lp(a)icosapent ethyltriglycerides

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.2K

Related Experiment Videos

Last Updated: Jun 29, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Elevated lipoprotein(a) [Lp(a)] is a significant risk factor for cardiovascular events, even with controlled LDL cholesterol.
  • Few therapeutic options exist to mitigate this residual risk.
  • Icosapent ethyl (IPE) is an investigational drug for cardiovascular risk reduction.

Purpose of the Study:

  • To analyze the cardiovascular benefits of icosapent ethyl (IPE) across various lipoprotein(a) [Lp(a)] levels.
  • To evaluate the efficacy of IPE in reducing major adverse cardiovascular events (MACE) in patients with different Lp(a) concentrations.

Main Methods:

  • Post hoc analysis of the REDUCE-IT trial involving 8,179 participants on statin therapy.
  • Participants had elevated triglycerides and controlled LDL cholesterol.
  • Randomization to IPE or placebo, with analysis of Lp(a) levels and MACE.

Main Results:

  • Lipoprotein(a) [Lp(a)] concentration was a significant predictor of major adverse cardiovascular events (MACE).
  • Icosapent ethyl (IPE) demonstrated consistent reduction in MACE across all analyzed Lp(a) levels.
  • IPE significantly reduced first MACE in subgroups with Lp(a) ≥50 mg/dL and <50 mg/dL.

Conclusions:

  • Baseline lipoprotein(a) [Lp(a)] concentration is prognostic for major adverse cardiovascular events (MACE) in patients with elevated triglycerides on statin therapy.
  • Icosapent ethyl (IPE) provides consistent cardiovascular risk reduction across a spectrum of Lp(a) levels.
  • IPE may be a valuable therapeutic option for patients with elevated Lp(a) and residual cardiovascular risk.